Last edition
News about
Mankind Pharma Q2 Net Profit Falls 21 Percent to INR 520 Crore
Mankind Pharma reported a 21 percent year-on-year decline in consolidated net profit for the quarter ended September 30, 2025, with profit falling to approximately INR 520 crore from INR 661 crore in the same period last year.
US FDA Grants Six More Priority Review Vouchers to Accelerate Drug Approvals
The US Food and Drug Administration (FDA) has awarded six additional companies under its “Commissioner’s National Priority Voucher” programme, bringing the total number of recipients to fifteen.
Valiant Advanced Sciences Begins Commercial Operations at New Greenfield Facility in Gujarat
According to Valiant Advanced Sciences, the new plant is dedicated to the production of Acetic Anhydride, a key chemical in the Ketene and Diketene derivatives category, serving both domestic and international markets.
Alembic Pharmaceuticals Receives USFDA Approval for Generic Dasatinib Tablets
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
Jaya Biosciences Receives US Patent for Novel Methods of Treating Neurological Diseases
US patent grant to Jaya Biosciences broadens protection and strengthens the company’s leadership in developing CNS-directed therapies for genetically defined neurodegenerative diseases.
Nona Biosciences and Umoja Biopharma Expand Partnership to Advance In-vivo CAR-T Therapies
Under the terms of the agreement, Nona Biosciences is eligible to receive an upfront payment, potential option exercise fees and milestone payments tied to the discovery and development of specific programmes in the collaboration. Umoja will be responsible for all further product development and commercialisation.
Cencora to Invest USD 1 Billion to Expand US Pharmaceutical Distribution Network
As part of its investments, Cencora plans to open a second national distribution centre in Ohio, which is expected to be fully operational by spring 2027.
Harbour BioMed and Evinova China Partner to Accelerate AI-Enabled Drug Development
Under the agreement, Harbour BioMed and Evinova China will combine their respective strengths to build an open ecosystem for AI-driven drug research and development.
Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth
Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.
DARZALEX FASPRO is the first and only approved treatment for high-risk smoldering multiple myeloma, according to Johnson & Johnson.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy